Aptorum Group

$2.33
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-2.92%) Today
$0.00 (0.00%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell Aptorum Group and other stocks, options, and ETFs commission-free!

About APM

Aptorum Group Limited Class A Ordinary Shares, also called Aptorum Group, is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, metabolic disorders, women's health and other disease areas. The Non-Therapeutics segment encompasses the development of surgical robotics and medical devices; operates the activities of AML Clinic; and sale of natural supplement. The firm’s pipe line is enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets. It also has projects focused on natural supplement for women undergoing menopause and experiencing related symptoms. The company was founded by Ian Huen on September 13, 2010 and is headquartered in London, the United Kingdom. The listed name for APM is Aptorum Group Limited Class A Ordinary Shares.

CEO
Ian Huen
Employees
37
Headquarters
London, Greater London
Founded
2010
Market Cap
79.25M
Price-Earnings Ratio
Dividend Yield
Average Volume
295.83K
High Today
$2.46
Low Today
$2.31
Open Price
$2.38
Volume
208.30K
52 Week High
$18.25
52 Week Low
$1.16

Collections

APM Earnings

-$0.33
-$0.22
-$0.11
$0.00
Q4 FY18
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Estimated
per share
Actual
Available Sep 1, Pre-Market

You May Also Like